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ABSTRACT 
The aims of this network are to collect epidemiological data of PcP cases in 14 hospitals in the Paris area 
and to determine the Di-Hydro Pteroate Synthase (DHPS) genotypes, genetic marker for possible 
sulfamide resistance. 
From 01/01/2003 to 12/31/2007, 805 (mean: 161/year) PcP cases have been reported. 61% of patients 
were HIV-positive. The median count of CD4 lymphocytes was 32/mm3 (30 in HIV-positive patients, 
158 in HIV-negative patients). In HIV-positive patients, PCP revealed the HIV infection in 39 %. Among 
211 PCP occurring in HIV known infected patients, no prophylaxis was prescribed for 72 %; 
cotrimoxazole prophylaxis had been prescribed to 39 patients but only one of them had the right 
compliance. In HIV-negative patients (264), corticosteroids were prescribed in 54 % and chemotherapy in 
36 %; 93 % did not receive prophylaxis. 128 tumoral pathologies and 86 transplantations were notified. 
The mortality rate was 16% at day 14 (13% in HIV-positive patients, 26% in HIV-negative patients). 
Mutations in DHPS genes were detected in 51 samples; 33 patients were infected with several strains. 
Total annual number of cases has been stable for five years but the proportion of HIV-negative patients 
increased from 25% to 41%. 
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INTRODUCTION 
Despite a decrease in incidence associated with the introduction of the high antiretroviral therapies 
(HAART), pneumocystosis due to Pneumocystis jirovecii (or PcP for Pneumocystis pneumonia) remains 
one of the main fungal infection diagnosed in Europe in AIDS and other immunocompromised patients 
[1, 2]. Due to strict host-species specificity, humans may be the main source of Pneumocystis jirovecii 
organisms and human-to-human and nosocomial transmission may occur [3]. Before the HAART era, 
HIV infection represented the main predisposing factors depending on the number of CD4 cells/ml. 
Genetic markers for possible sulfamide/sulfone-resistance (point mutations 165 and 171 of P. jirovecii 
dihydropteroate synthase (DHPS) gene, encoding for amino acid 55 and 57 of the protein) have been 
reported and are still debated [4]. The aims of this study were to revaluate the epidemiological 
characteristics of pneumocystosis in the Paris area and to analyse the relation between point mutation(s) 
in the DHPS gene and the breakthrough of prophylaxis. 
 
MATERIALS AND METHODS 
A network was initiated in 2003 to collect demographic and epidemiological data related to the cases of 
pneumocystosis diagnosed in 14 University hospitals of Assistance Publique - Hôpitaux de Paris (AP-
HP). Microscopic observations of bronchoalveolar lavage fluid (BALF) samples taken from these patients 
were performed using standard methods. These included Giemsa staining and the use of commercially 
available fluorescein-labeled monoclonal anti-Pneumocystis antibodies (BIORAD, Monofluokit 
Pneumocystis carinii) of BALF smears. Microscopic detection of the organism was taken as proof of PcP 
diagnosis. The following data were collected : date of birth, sex, department where analysis was 
performed, HIV serological status, PcP as HIV-revealing infection, immunosuppression due to other than 
HIV infection, solid organ transplantation information, tumor pathologies, immunosuppressive 
treatments, genetic immunodeficiency, date when the sample that revealed PcP was taken, first episode of 
PcP or no previous diagnosis, prophylaxis, intolerance or compliance to cotrimoxazole, CD4+ 
lymphocyte counts, initial treatment of PcP, and clinical progression. In addition, samples were analysed 
to determine DHPS genotypes (mutations at positions 165 and 171) using PCR direct sequencing. 
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RESULTS 
From 01/01/2003 to 12/31/2008, 993 cases of PcP were reported (mean : 166 cases/year). The sex ratio 
was 2.2 and the median age was 47 years. Sixty-five % of the patients were HIV-positive. Among them, 
the HIV infection was already known in 304 patients, while pneumocystosis revealed the retroviral 
infection in 39% of the cases. The median count of CD4 lymphocytes was 30/mm3 +/- 89/mm3 (range 
from 0 to 694). PcP was a first episode in 91.5%. HIV-positive patients had not received any anti-
Pneumocystis chemoprophylaxis at the time of pneumocystosis diagnosis in 64% of the cases. In the 
remaining cases, cotrimoxazole prophylaxis had been prescribed to 47 patients but only one of them had a 
right compliance. Drug intolerance was observed in 20.5% of these patients. When pyrimethamine + 
dapsone, atovaquone or pentamidine were used as prophylaxis, treatments were stopped in half cases 
because of intolerance to these drugs. 
The proportion of HIV-negative patients (n = 264) increased from 25% of the cases in 2003 to 43% in 
2008 (figure 1). The CD4+ lymphocytes count was 152/mm3 +/- 264/mm3 (range from 0 to1000). In these 
patients, PcP was a first episode in 97.3% of cases. The main underlying diseases or risk factors were: 
haematological malignancies (73 leukemias, 51 lymphomas, 10 Hodgkin’s diseases, 29 bone marrow 
transplantations, 5 myelomas), tumoral pathologies (169) and solid organ transplantations (116 
transplantations; kidney : 48, heart :15: liver : 12, lung : 1). Fifty-nine % of the patients received 
corticosteroid therapy and 34% cytotoxic chemotherapies. Except tumoral pathologies and 
transplantations, the most frequent pathologies in HIV-negative patients were lupus (5), SCID (5), 
sarcoidosis (3), cirrhosis (3), dermatomyositis (3). Seventy-eight % of the HIV-negative patients had not 
received any anti-Pneumocystis prophylaxis. 
Mortality at day 14 was 26% in HIV- negative patients versus 13% in HIV-positive patients. When the 
diagnosis of PcP was performed, 44 % of HIV-negative patients and 26% of HIV-positive patients were 
in units of intensive care.  
Forty-two % of specimens were available for DHPS genotyping. Forty six (14%) of the samples did not 
amplify. Mutations in DHPS genes were detected in 18,5% of samples. Co-infections with at least two 
different strains were observed in 12,5% of the isolates. Double mutation (at positions 165 and 171) was 
present in 9.5%. No significant relationship was observed between mutation and outcome or mortality, 
nor between mutation and prophylaxis. 
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DISCUSSION 
From 01/01/2003 to 12/31/2008, the incidence of PcP in the Paris area is stable despite prophylaxis and 
frequent use of HAART in HIV-infected patients. It confirms previous data in 2003-2004 in the same 
geographical area [5]. PcP still often reveals HIV infection (39% of the cases) indicating extensive lack of 
HIV status testing. Among known HIV-infected patients when PcP was diagnosed, prophylaxis is often 
missing (64%) or not in compliance when used.  
The proportion of HIV-negative patients increased continuously from 2003 to 2008. The main risk factors 
in HIV-negative patients were corticotherapy and chemotherapies. Cotrimoxazole is difficult to use in 
case of haematological malignancies because of its cytological side effects. Alternative drugs with their 
own side effects are less effective against Pneumocystis. The CD4+ lymphocytes count is less relevant in 
these patients for PcP risk managing because the mechanisms of immunosuppression are different than in 
HIV infection [1]. 
Genotyping for DHPS gene was not effective for 14% of the specimens without any amplification; this is 
due to the fact that DHPS is present in single copy. The prevalence of DHPS mutations varies with 
geographic location and could be related to the frequency of chemotherapeutic drugs used to clear PcP 
[6]. In our survey, no significant relationship was observed between mutation and outcome or mortality, 
or between mutation and prophylaxis. Indeed, mutations were detected in patients without prophylaxis. In 
9.5 % of the isolates, mutations were detected in both sites (165 and 171). Expression mutant genes in 
recombinant Saccharomyces cerevisiae systems showed that the presence of two mutations results in 
higher resistance than the presence of only one [6]. An initial mutation in P. jirovecii DHPS might first 
occur in drug-treated patients without clinical consequences and later other mutations could come about 
leading to the spread of organisms with high resistance to cotrimoxazole. So, the risk of emergence of 
resistant strains exists and epidemiological surveillance is needed  
Despite risk factors and effective prophylaxis being known, PcP remains a frequent fungal disease 
associated with AIDS and in other immunocompromised patients as well. PcP still often reveals HIV 
infection at a late stage. Prophylaxis needs to be prescribed in patients receiving long-term corticosteroid 
treatment.  
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Figure 1. HIV serological status 
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